Datum Källa Rubrik Typ Alternativ
2024-05-02 Initiator Pharma Notice to AGM in Initiator Pharma Pressreleaser Ladda ner | Visa Stäng
2024-05-02 Initiator Pharma Annual report and Remuneration report 2023 for Initiator Pharma A/S Rapporter Ladda ner | Visa Stäng
2024-05-02 Initiator Pharma Årsredovisning och ersättningsrapport 2023 för Initiator Pharma A/S Rapporter Ladda ner | Visa Stäng
2024-04-12 Initiator Pharma Initiator Pharmas prekliniska farmakologiska resultat med pudafensine publiceras i British Journal of Pharmacology Pressreleaser Ladda ner | Visa Stäng
2024-04-12 Initiator Pharma Initiator Pharma’s pudafensine preclinical pharmacology results published in the British Journal of Pharmacology Pressreleaser Ladda ner | Visa Stäng
2024-02-26 Penser Access by Carnegie Penser Access by Carnegie: Intervju med Initiator Pharma - Carnegie Investment Bank - 26 feb 2024 Pressreleaser Visa Stäng
2024-02-23 Redeye Redeye: Initiator Pharma - Q4 2023 – Breathing optimism Pressreleaser Ladda ner | Visa Stäng
2024-02-23 Initiator Pharma INITIATOR PHARMA: YEAR END REPORT 2023 Rapporter Ladda ner | Visa Stäng
2024-02-23 Initiator Pharma INITIATOR PHARMA: BOKSLUTSKOMMUNIKÉ 2023 Rapporter Ladda ner | Visa Stäng
2024-02-21 Initiator Pharma MAC Clinical Research konverterar sin fordran till aktier i Initiator Pharma Pressreleaser Ladda ner | Visa Stäng
2024-02-21 Initiator Pharma MAC Clinical Research converts its receivable into shares in Initiator Pharma Pressreleaser Ladda ner | Visa Stäng
2024-01-23 Initiator Pharma Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021 Pressreleaser Ladda ner | Visa Stäng
Pressreleaser | 23 Jan 2024 | Initiator Pharma

Issuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021

The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or the “Company”) has today resolved to carry out a capital increase directed at members of executive management and key management under the long term incentive program for 2021 (“LTI2021-program”) and to conduct a directed buyback of shares in order to sell shares to the board of directors under the LTI2021-program.

The company’s board has today decided on the allocation of Performance Shares in accordance with terms of the LTI2021-program. In this connection, the Company has received subscription commitments from members of the executive management and key management, as well as a request to purchase existing shares from certain members of the Board of Directors. As such, the Board of Directors has today conducted a capital increase and decided to implement a share buy back directed at members of management as further described below.

The overall purpose of the Company’s incentive programs is to align the interests of the participants with the interests of the shareholders and thereby ensure a maximum long-term, value-creating commitment. It is also considered to create a long-term focus on increased earnings and growth among the participants in the program. Furthermore, incentive programs are considered to make it easier for the Company to recruit and retain key personnel.

Issuance of new shares and capital increase

The Company’s share capital has been increased by a total of nominally DKK 54,527.24 divided into 519,307 shares (the “New Shares”) as a result of a share issue to certain members of executive management and key management under the LTI2021-program. The shares have been issued subject to the board authorisation in article 4d in the Company’s articles of association.

The capital increase in connection with the subscription of shares by certain members of executive management and key management amounts to DKK 54,527.24 corresponding to 519,307 shares of nominally DKK 0.105. The 519,307 shares have been subscribed for by cash contribution at a price of DKK 0.105 per share and as a result the Company’s gross proceeds amounts to a total of DKK 54,527.24.

The New Shares are subject to the same rights as existing shares under the Company’s articles of association and are expected to be admitted to trading on Nasdaq First North Growth Market under the existing ISIN code DK0060775872.

After the capital increase, the total nominal value of the Company’s share capital amounts to nominally DKK 5,564,075.370 divided into 52,991,194 shares of nominally DKK 0.105 each corresponding to 52,991,194 votes.

The Company’s updated articles of association will be made available on the Company’s website.

Implementation of a share buyback specifically targeted towards members of the management team

Today the Board of Directors in the Company also resolved to conduct a share buy-back directed towards members of the management team in order for the Company to be able to sell treasury shares to certain members of the Board of Directors under the LTI2021-program. The total number of shares that the Company intends to buy from members of management and consequently sell to certain members of the Board of Directors is 98.915. Each share will be acquired at a fixed price of SEK 8.94 corresponding to the volume weighted average price on the Company’s share for a period of 14 trading days. The Company will sell the shares to certain members of the Board of Directors at a price of DKK 0.105 per share corresponding to par value.

The share buy-back directed at certain members of management will be conducted subject to the authorisation to the Board of Directors to acquire treasury shares under section 198 of the Danish Companies Act. The authorisation was granted at the Annual General Meeting held on 26 May 2023 and it is anticipated to be finalized within a week. There will be no separate company announcement upon completion of the buy back and the delivery of the shares.

The company’s board has decided to acquire the shares from the Company’s management to assist the management in meeting a tax liability associated with their subscription of shares. Additionally, this decision aims to avoid a share buyback program targeted at the market, which could disrupt the liquidity of the share and necessitate the involvement of an investment bank, incurring additional costs.

Notifications from PDMR’s

The Company has received the attached notifications pursuant to Article 19 of the Market Abuse Regulation from persons discharging managerial responsibilities and persons closely related to a person discharging managerial responsibilities.

2024-01-23 Initiator Pharma Nyemission och riktat aktieåterköp samt försäljning av aktier i samband med det långsiktiga incitamentsprogrammet för 2021 Pressreleaser Ladda ner | Visa Stäng
2024-01-08 Initiator Pharma Initiator Pharma expands its position to a broader Sexual Health Franchise and intensifies its business development efforts Pressreleaser Ladda ner | Visa Stäng
2024-01-08 Initiator Pharma Initiator Pharma utvidgar sin position till en bredare franchise inom sexuell hälsa och intensifierar affärsutvecklingsarbetet Pressreleaser Ladda ner | Visa Stäng
2023-11-13 Penser Access Penser Access: Positiv utveckling - mer på agendan i år - Initiator Pharma Pressreleaser Visa Stäng
2023-11-10 Redeye Redeye: Initiator Pharma Q3 - A historical quarter Pressreleaser Ladda ner | Visa Stäng
2023-11-10 Initiator Pharma INITIATOR PHARMA: Q3 2023 REPORT Rapporter Ladda ner | Visa Stäng
2023-11-10 Initiator Pharma INITIATOR PHARMA: RAPPORT FÖR TREDJE KVARTALET 2023 Rapporter Ladda ner | Visa Stäng
2023-10-18 Initiator Pharma Initiator Pharma presenterar på BioStock Life Science Summit den 25 oktober Pressreleaser Visa Stäng
2023-10-10 Redeye Redeye: Initiator Pharma - Positive Phase IIb results Pressreleaser Ladda ner | Visa Stäng
2023-10-09 Penser Access Penser Access: Levererar positiva resultat - Initiator Pharma Pressreleaser Visa Stäng
2023-10-09 Penser Access Penser Access: Interview with Initiator Pharma - Erik Penser Bank - Oct 9th 2023 Pressreleaser Visa Stäng
2023-10-06 Initiator Pharma Initiator Pharma reports positive statistically significant and clinically relevant Phase IIb efficacy data with pudafensine Pressreleaser Ladda ner | Visa Stäng
2023-10-06 Initiator Pharma Initiator Pharma rapporterar positiva, statistiskt signifikanta och kliniskt relevanta fas IIb-effektdata för pudafensine Pressreleaser Ladda ner | Visa Stäng
2023-09-25 Initiator Pharma Utnyttjande i Initiator Pharmas incitamentsprogram LTI2023 Pressreleaser Ladda ner | Visa Stäng
2023-09-25 Initiator Pharma Result of incentive program LTI2023 in Initiator Pharma Pressreleaser Ladda ner | Visa Stäng
2023-09-22 Penser Access Penser Access: Interview with Initiator Pharma - Erik Penser Bank - Sep 21st 2023 Pressreleaser Visa Stäng
2023-09-19 Initiator Pharma Initiator Pharma announces indication expansion – clinical drug candidates active in models of female sexual dysfunction Pressreleaser Ladda ner | Visa Stäng
2023-09-19 Initiator Pharma Initiator Pharma meddelar indikationsutvidgning av båda sina kliniska läkemedelskandidater till kvinnor med sexuell dysfunktion Pressreleaser Ladda ner | Visa Stäng
2023-08-25 Redeye Redeye: Initiator Pharma Q2 2023 - Development progres Pressreleaser Ladda ner | Visa Stäng
2023-08-25 Initiator Pharma INITIATOR PHARMA: Q2 2023 REPORT Rapporter Ladda ner | Visa Stäng
2023-08-25 Initiator Pharma INITIATOR PHARMA: RAPPORT FÖR ANDRA KVARTALET 2023 Rapporter Ladda ner | Visa Stäng
2023-08-09 Initiator Pharma Initiator Pharma obtains IP2018 patent in Europe for treatment of Erectile Dysfunction and Depression Pressreleaser Ladda ner | Visa Stäng
2023-08-09 Initiator Pharma Initiator Pharma erhåller patent i Europa för IP2018 mot erektil dysfunktion och depression Pressreleaser Ladda ner | Visa Stäng
2023-07-18 Initiator Pharma Initiator Pharma announces positive results from pudafensine Phase I pharmacokinetic trial Pressreleaser Ladda ner | Visa Stäng
2023-07-18 Initiator Pharma Initiator Pharma meddelar positiva resultat från farmakokinetisk fas I-studie med pudafensin Pressreleaser Ladda ner | Visa Stäng
2023-07-05 Initiator Pharma Finalization of share buyback program in Initiator Pharma Pressreleaser Ladda ner | Visa Stäng
2023-07-05 Initiator Pharma Slutförande av aktieåterköpsprogram i Initiator Pharma Pressreleaser Ladda ner | Visa Stäng
2023-06-29 Initiator Pharma Initiator Pharma completes recruitment in Phase IIb trial with pudafensine (IP2015) Pressreleaser Ladda ner | Visa Stäng
2023-06-29 Initiator Pharma Initiator Pharma slutför rekryteringen i fas IIb-studie med pudafensine (IP2015) Pressreleaser Ladda ner | Visa Stäng
2023-06-21 Initiator Pharma Issuance of new shares, share buyback and sale of shares in connection with long term incentive program for 2022 Pressreleaser Ladda ner | Visa Stäng
2023-06-21 Initiator Pharma Emission av nya aktier, återköp och försäljning av aktier i samband med långsiktigt incitamentsprogram för 2022 Pressreleaser Ladda ner | Visa Stäng
2023-06-14 Penser Access Penser Access: Positiva resultat stärker caset - Initiator Pharma Pressreleaser Visa Stäng
2023-06-05 Initiator Pharma Initiator Pharma reports dose-dependent significant efficacy of IP2018 in the placebo-controlled Phase IIa clinical trial of Erectile Dysfunction Pressreleaser Ladda ner | Visa Stäng
2023-06-05 Initiator Pharma Initiator Pharma rapporterar positiva dosberoende och signifikanta effektdata i den kliniska fas IIa-studien med IP2018 Pressreleaser Ladda ner | Visa Stäng
2023-05-31 Initiator Pharma BioStock Life Science Spring Summit with Initiator Pharma Pressreleaser Visa Stäng
2023-05-31 Initiator Pharma BioStock Life Science Spring Summit med Initiator Pharma Pressreleaser Visa Stäng
2023-05-30 Initiator Pharma Initiator Pharma’s IP2015 obtains the International Nonproprietary Name pudafensine Pressreleaser Ladda ner | Visa Stäng
2023-05-30 Initiator Pharma Initiator Pharma erhåller det internationella generiska namnet pudafensine för IP2015 Pressreleaser Ladda ner | Visa Stäng
2023-05-26 Initiator Pharma Initiator Pharma A/S - Resolutions of the annual general meeting 2023 Pressreleaser Ladda ner | Visa Stäng

Kommande händelser

10 May 2024 | Kvartalsrapport 2024-Q1
24 May 2024 | Årsstämma 2023
27 May 2024 | Årligutdelning
23 Aug 2024 | Kvartalsrapport 2024-Q2
15 Nov 2024 | Kvartalsrapport 2024-Q3
28 Feb 2025 | Bokslutskommuniké 2024